Galenica AG

GALE

CH0360674466

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
70.85 ^CHF	+0.71%		+0.93%	-2.61%

Apr. 17	Switzerland's Galenica Issues CHF100 Million Bond Due 2031	MT
Mar. 14	GALENICA : FY23 one-offs shroud decent underlying profitability growth

Galenica : Management structure

February 26, 2024

1)
		1)

Virginie Pache Jeschka	Daniele Madonna	Thomas Szuran	Andreas Koch	Lukas Ackermann
Pharmacies*	Healthcare*	Products & Marketing*	Wholesale & Logistics*	IT & Digital Services*

Felix Burkhard	Arianne Hasler	Christina Hertig	Barbara Wälchli	Jürg Pauli
Finance*	People & Culture*	Corporate Communications**	Legal & Board Services**	Transformation**

Marc Werner

CEO Galenica*

Executive Committee
extended Executive Comittee
1) Joint Venture

Attachments

Original Link
Original Document
Permalink

Disclaimer

Galenica AG published this content on 27 February 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 March 2024 15:44:08 UTC.

Latest news about Galenica AG

Switzerland's Galenica Issues CHF100 Million Bond Due 2031	Apr. 17	MT
GALENICA : FY23 one-offs shroud decent underlying profitability growth	Mar. 14
Swiss Stocks Shrug Off Sticky US Inflation Report	Mar. 12	MT
Galenica AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Transcript : Galenica AG, 2023 Earnings Call, Mar 12, 2024	Mar. 12
Galenica Posts Rise in FY23 Attributable Profit, Sales	Mar. 12	MT
Galenica AG acquired 33% stake in Farmadomo Home Care Provider SA.	Mar. 10	CI
GALENICA : In-line FY23 sales validate our cautious stance	Jan. 24
Global markets live: Flutter, Humana, Bayer, KKR, Boeing...	Jan. 18
Galenica Posts Rise in FY23 Sales; Dividend Outlook Affirmed	Jan. 18	MT
Research Partners Lifts Price Target on Galenica, Maintains Hold Recommendation	23-10-27	MT
GALENICA : H1 23: Broad-based top-line momentum, underlying EBIT trends unchanged	23-08-15
Global markets live: Abrdn, Beyond Meat, Novavax, Under Armour, Lucid...	23-08-08
Transcript : Galenica AG, H1 2023 Earnings Call, Aug 08, 2023	23-08-08
Galenica AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-08	CI
Galenica Records Gain in H1 Profit, Sales	23-08-08	MT
Redcare Pharmacy raises revenue and margin forecast	23-08-01	DP
Galenica to Buy 16% Stake in E-health Provider AD Swiss	23-06-05	MT
Galenica AG acquired AD Swiss Net AG.	23-06-04	CI
Shop Apotheke Europe Receives Regulatory Nod for Galenica JV	23-05-12	MT
Strong start to the year for Shop Apotheke - Board of Management confirms targets	23-05-02	DP
Transcript : Galenica AG, Shop Apotheke Europe N.V. - Shareholder/Analyst Call	23-03-30
GALENICA : Light FY 22 earnings and a soft FY 23 outlook disappoint investors	23-03-07
Transcript : Galenica AG, 2022 Earnings Call, Mar 07, 2023	23-03-07
Galenica Posts Lower FY22 Attributable Net Profit	23-03-07	MT

Chart Galenica AG

Duration

Period

More charts

Company Profile

Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GALENICA : FY23 one-offs shroud decent underlying profitability growth

March 14, 2024 at 09:38 am EDT

More Strategies

Ratings for Galenica AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

70.85 CHF

Average target price

76.25 CHF

Spread / Average Target

+7.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
GALENICA AG	-2.61%	3.86B
MCKESSON CORPORATION	+17.35%	71.39B
SINOPHARM GROUP CO. LTD.	+5.38%	8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.69%	8.19B
HUADONG MEDICINE CO., LTD	-20.96%	7.91B
H. LUNDBECK A/S	+0.49%	4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.31B
EBOS GROUP LIMITED	-3.38%	3.93B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+22.08%	3.64B
MEDIPAL HOLDINGS CORPORATION	+7.96%	3.29B

Pharmaceuticals Wholesale

Galenica AG

Equities

GALE

CH0360674466

Pharmaceuticals

Galenica : Management structure

EPS Revisions